



Universiteit
Leiden
The Netherlands

Targeted therapy in oncology: mechanisms and toxicity

Steeeghs, N.

Citation

Steeeghs, N. (2009, November 24). *Targeted therapy in oncology: mechanisms and toxicity*. Retrieved from <https://hdl.handle.net/1887/14431>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/14431>

Note: To cite this publication please use the final published version (if applicable).

Targeted therapy in oncology: mechanisms and toxicity

Neeltje Steeghs

Targeted therapy in oncology: mechanisms and toxicity

ISBN/EAN: 978-90-9024614-7

Lay-out: Grafisch bureau Christine van der Ven, Voorschoten

Printed by: Gildeprint Drukkerijen, Enschede

Financial support for printing this thesis by SKOL (Stichting Klinische Oncologie Leiden), AZL Onderzoeks- en Ontwikkelingskrediet Apotheek, Abbott, Amgen, Astra Zeneca, Bayer Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag, Merck, Merck Sharp & Dohme, Nerviano MS, Novartis, Pfizer, Sanofi-Aventis, and Wyeth is gratefully acknowledged

© 2009 Neeltje Steeghs, Leiderdorp, The Netherlands

Targeted therapy in oncology: mechanisms and toxicity

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 24 november 2009
klokke 15.00 uur

door
Neeltje Steeghs
geboren te Breda in 1977

PROMOTIECOMMISSIE

Promotores: Prof. Dr. J.W.R. Nortier
Prof. Dr. H.-J. Guchelaar

Copromotor: Dr. A.J. Gelderblom

Leden: Prof. Dr. M. Danhof
Prof. Dr. A.J. Rabelink
Prof. Dr. J.H.M. Schellens

CONTENTS

Chapter 1	General introduction and outline of the thesis.....	7
Chapter 2	Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments <i>Ann Surg Oncol. 2007 Feb;14(2):942-53</i>	13
Chapter 3	EGFR and ERBB2 expression in sarcomas: the search for new treatment options.	35
Chapter 4	A phase I dose escalation study of telatinib (BAY 57-9352), a tyrosine kinase inhibitor of VEGFR-2, VEGFR-3, PDGFR- β and c-Kit, in patients with advanced or metastatic solid tumors <i>J Clin Oncol. 2009;27(15): 4188–4196.</i>	45
Chapter 5	Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors <i>Submitted</i>	63
Chapter 6	Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor..... <i>Clin Cancer Res. 2008 Jun 1;14(11):3470-6</i>	75
Chapter 7	Reversibility of capillary density after discontinuation of bevacizumab treatment..... <i>Ann Oncol, in press</i>	93
Chapter 8	Phase I dose escalation study of sunitinib in combination with ifosfamide..... <i>Study ongoing</i>	107
Chapter 9	A phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor PHA-739358 in patients with advanced or metastatic solid tumors <i>J Clin Oncol, in press</i>	125

Chapter 10 Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor PHA-739358	145
<i>Submitted</i>	
Chapter 11 General discussion	161
Summary	167
Samenvatting	173
Nawoord	179
Curriculum vitae	183
Publications.....	187